Synthekine vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Synthekine engineers selective cytokine therapeutics for cancer and autoimmune disease; $289M raised, Phase 2 SYNERGY-101 trial underway, FDA Fast Track for lupus program, 50% response rate in NSCLC Phase 1b.
About
Synthekine is a clinical-stage biotechnology company engineering next-generation cytokine therapeutics designed to harness the immune system's most powerful signaling molecules against cancer and autoimmune disease — without the severe toxicities that have historically limited cytokine drugs. Cytokines like interleukin-2 (IL-2) are known to activate potent anti-tumor immune responses, but their systemic pleiotropic effects cause dose-limiting toxicities when administered as conventional drugs. Synthekine's protein engineering platforms create partially agonized or receptor-selective cytokine variants that stimulate only the desired immune cell populations, dramatically improving the therapeutic window.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.